ZA200610168B - Compositions comprising flavonoids and tocotrienols and methods thereof - Google Patents

Compositions comprising flavonoids and tocotrienols and methods thereof Download PDF

Info

Publication number: ZA200610168B
Authority: ZA; South Africa
Prior art keywords: pharmaceutical formulation; formulation according; pharmaceutical; lowers; administration
Prior art date: 2004-05-26

Application number

ZA200610168A

Other languages

English (en)

Inventor

Guthrie Najla

Original Assignee

Kgk Synergize Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-05-26

Filing date

2005-05-24

Publication date

2008-06-25

2005-05-24 Application filed by Kgk Synergize Inc filed Critical Kgk Synergize Inc

2008-06-25 Publication of ZA200610168B publication Critical patent/ZA200610168B/en

Links

150000002215 flavonoids Chemical class 0.000 title claims abstract description 64
229930003935 flavonoid Natural products 0.000 title claims abstract description 63
235000017173 flavonoids Nutrition 0.000 title claims abstract description 63
229930003802 tocotrienol Natural products 0.000 title claims abstract description 58
239000011731 tocotrienol Substances 0.000 title claims abstract description 58
235000019148 tocotrienols Nutrition 0.000 title claims abstract description 58
GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 title claims abstract description 41
229940068778 tocotrienols Drugs 0.000 title claims abstract description 41
239000000203 mixture Substances 0.000 title claims description 77
238000000034 method Methods 0.000 title claims description 19
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 97
239000004615 ingredient Substances 0.000 claims abstract description 48
239000013543 active substance Substances 0.000 claims abstract description 31
239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 16
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 76
238000009472 formulation Methods 0.000 claims description 68
235000020971 citrus fruits Nutrition 0.000 claims description 31
235000012000 cholesterol Nutrition 0.000 claims description 29
YRCWQPVGYLYSOX-UHFFFAOYSA-N synephrine Chemical compound CNCC(O)C1=CC=C(O)C=C1 YRCWQPVGYLYSOX-UHFFFAOYSA-N 0.000 claims description 26
238000008214 LDL Cholesterol Methods 0.000 claims description 19
150000003626 triacylglycerols Chemical class 0.000 claims description 19
GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 claims description 17
201000001320 Atherosclerosis Diseases 0.000 claims description 14
229960003684 oxedrine Drugs 0.000 claims description 13
208000035150 Hypercholesterolemia Diseases 0.000 claims description 12
208000024172 Cardiovascular disease Diseases 0.000 claims description 10
ULSUXBXHSYSGDT-UHFFFAOYSA-N tangeretin Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 ULSUXBXHSYSGDT-UHFFFAOYSA-N 0.000 claims description 8
239000002775 capsule Substances 0.000 claims description 7
OTXNTMVVOOBZCV-UHFFFAOYSA-N 2R-gamma-tocotrienol Natural products OC1=C(C)C(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 OTXNTMVVOOBZCV-UHFFFAOYSA-N 0.000 claims description 6
241000207199 Citrus Species 0.000 claims description 6
229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 6
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 6
RZFHLOLGZPDCHJ-DLQZEEBKSA-N alpha-Tocotrienol Natural products Oc1c(C)c(C)c2O[C@@](CC/C=C(/CC/C=C(\CC/C=C(\C)/C)/C)\C)(C)CCc2c1C RZFHLOLGZPDCHJ-DLQZEEBKSA-N 0.000 claims description 6
AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims description 6
229940079593 drug Drugs 0.000 claims description 5
239000003814 drug Substances 0.000 claims description 5
229960003512 nicotinic acid Drugs 0.000 claims description 5
235000001968 nicotinic acid Nutrition 0.000 claims description 5
239000011664 nicotinic acid Substances 0.000 claims description 5
239000000725 suspension Substances 0.000 claims description 5
239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 claims description 4
OBIOZWXPDBWYHB-UHFFFAOYSA-N Nobiletin Natural products C1=CC(OC)=CC=C1C1=C(OC)C(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 OBIOZWXPDBWYHB-UHFFFAOYSA-N 0.000 claims description 4
108010073771 Soybean Proteins Proteins 0.000 claims description 4
IECRXMSGDFIOEY-UHFFFAOYSA-N Tangeretin Natural products COC=1C(OC)=C(OC)C(OC)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C=C1 IECRXMSGDFIOEY-UHFFFAOYSA-N 0.000 claims description 4
AIONOLUJZLIMTK-AWEZNQCLSA-N hesperetin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-AWEZNQCLSA-N 0.000 claims description 4
AIONOLUJZLIMTK-UHFFFAOYSA-N hesperetin Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-UHFFFAOYSA-N 0.000 claims description 4
235000010209 hesperetin Nutrition 0.000 claims description 4
229960001587 hesperetin Drugs 0.000 claims description 4
FTODBIPDTXRIGS-UHFFFAOYSA-N homoeriodictyol Natural products C1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 FTODBIPDTXRIGS-UHFFFAOYSA-N 0.000 claims description 4
WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 claims description 4
235000007625 naringenin Nutrition 0.000 claims description 4
229940117954 naringenin Drugs 0.000 claims description 4
MRIAQLRQZPPODS-UHFFFAOYSA-N nobiletin Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 MRIAQLRQZPPODS-UHFFFAOYSA-N 0.000 claims description 4
229940001941 soy protein Drugs 0.000 claims description 4
RZFHLOLGZPDCHJ-XZXLULOTSA-N α-Tocotrienol Chemical compound OC1=C(C)C(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1C RZFHLOLGZPDCHJ-XZXLULOTSA-N 0.000 claims description 4
OTXNTMVVOOBZCV-WAZJVIJMSA-N γ-tocotrienol Chemical compound OC1=C(C)C(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 OTXNTMVVOOBZCV-WAZJVIJMSA-N 0.000 claims description 4
ODADKLYLWWCHNB-LDYBVBFYSA-N δ-tocotrienol Chemical compound OC1=CC(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 ODADKLYLWWCHNB-LDYBVBFYSA-N 0.000 claims description 4
ODADKLYLWWCHNB-UHFFFAOYSA-N 2R-delta-tocotrienol Natural products OC1=CC(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 ODADKLYLWWCHNB-UHFFFAOYSA-N 0.000 claims description 3
229940064063 alpha tocotrienol Drugs 0.000 claims description 3
ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 3
BTNBMQIHCRIGOU-UHFFFAOYSA-N delta-tocotrienol Natural products CC(=CCCC(=CCCC(=CCCOC1(C)CCc2cc(O)cc(C)c2O1)C)C)C BTNBMQIHCRIGOU-UHFFFAOYSA-N 0.000 claims description 3
150000002211 flavins Chemical class 0.000 claims description 3
OTXNTMVVOOBZCV-YMCDKREISA-N gamma-Tocotrienol Natural products Oc1c(C)c(C)c2O[C@@](CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)(C)CCc2c1 OTXNTMVVOOBZCV-YMCDKREISA-N 0.000 claims description 3
235000002532 grape seed extract Nutrition 0.000 claims description 3
229940087603 grape seed extract Drugs 0.000 claims description 3
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 3
235000019136 lipoic acid Nutrition 0.000 claims description 3
239000007788 liquid Substances 0.000 claims description 3
235000012680 lutein Nutrition 0.000 claims description 3
229960005375 lutein Drugs 0.000 claims description 3
239000001656 lutein Substances 0.000 claims description 3
KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims description 3
ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims description 3
235000020741 pine bark extract Nutrition 0.000 claims description 3
229940106587 pine bark extract Drugs 0.000 claims description 3
235000003687 soy isoflavones Nutrition 0.000 claims description 3
235000013616 tea Nutrition 0.000 claims description 3
229960002663 thioctic acid Drugs 0.000 claims description 3
KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims description 3
239000001717 vitis vinifera seed extract Substances 0.000 claims description 3
FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims description 3
235000019145 α-tocotrienol Nutrition 0.000 claims description 3
239000011730 α-tocotrienol Substances 0.000 claims description 3
235000019150 γ-tocotrienol Nutrition 0.000 claims description 3
239000011722 γ-tocotrienol Substances 0.000 claims description 3
235000019144 δ-tocotrienol Nutrition 0.000 claims description 3
239000011729 δ-tocotrienol Substances 0.000 claims description 3
FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 claims description 2
XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims description 2
XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims description 2
PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims description 2
TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims description 2
RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims description 2
229960005370 atorvastatin Drugs 0.000 claims description 2
229960005110 cerivastatin Drugs 0.000 claims description 2
SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 claims description 2
239000000839 emulsion Substances 0.000 claims description 2
229960003765 fluvastatin Drugs 0.000 claims description 2
229960004844 lovastatin Drugs 0.000 claims description 2
PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims description 2
QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims description 2
229960002965 pravastatin Drugs 0.000 claims description 2
TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims description 2
229960002855 simvastatin Drugs 0.000 claims description 2
RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims description 2
241001122767 Theaceae Species 0.000 claims 2
FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 claims 1
238000011282 treatment Methods 0.000 description 13
108010007622 LDL Lipoproteins Proteins 0.000 description 12
102000007330 LDL Lipoproteins Human genes 0.000 description 12
102000004895 Lipoproteins Human genes 0.000 description 9
108090001030 Lipoproteins Proteins 0.000 description 9
235000013399 edible fruits Nutrition 0.000 description 9
239000003921 oil Substances 0.000 description 9
235000019198 oils Nutrition 0.000 description 9
150000002632 lipids Chemical class 0.000 description 8
108010010234 HDL Lipoproteins Proteins 0.000 description 7
102000015779 HDL Lipoproteins Human genes 0.000 description 7
208000029078 coronary artery disease Diseases 0.000 description 7
-1 fatty acid esters Chemical class 0.000 description 7
239000000243 solution Substances 0.000 description 7
239000003826 tablet Substances 0.000 description 7
208000031226 Hyperlipidaemia Diseases 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 5
240000000560 Citrus x paradisi Species 0.000 description 5
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
210000004369 blood Anatomy 0.000 description 5
239000008280 blood Substances 0.000 description 5
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
235000010208 anthocyanin Nutrition 0.000 description 4
239000004410 anthocyanin Substances 0.000 description 4
229930002877 anthocyanin Natural products 0.000 description 4
150000004636 anthocyanins Chemical class 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
230000034994 death Effects 0.000 description 4
231100000517 death Toxicity 0.000 description 4
235000005911 diet Nutrition 0.000 description 4
239000000499 gel Substances 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
FTVWIRXFELQLPI-CYBMUJFWSA-N (R)-naringenin Chemical compound C1=CC(O)=CC=C1[C@@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-CYBMUJFWSA-N 0.000 description 3
102000007592 Apolipoproteins Human genes 0.000 description 3
108010071619 Apolipoproteins Proteins 0.000 description 3
241000675108 Citrus tangerina Species 0.000 description 3
244000286241 Kunzea pomifera Species 0.000 description 3
241000124008 Mammalia Species 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
235000003599 food sweetener Nutrition 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
239000002245 particle Substances 0.000 description 3
150000003904 phospholipids Chemical class 0.000 description 3
239000001267 polyvinylpyrrolidone Substances 0.000 description 3
229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
239000000843 powder Substances 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
239000003765 sweetening agent Substances 0.000 description 3
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
JPFCOVZKLAXXOE-XBNSMERZSA-N (3r)-2-(3,5-dihydroxy-4-methoxyphenyl)-8-[(2r,3r,4r)-3,5,7-trihydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2h-chromen-4-yl]-3,4-dihydro-2h-chromene-3,5,7-triol Chemical compound C1=C(O)C(OC)=C(O)C=C1C1[C@H](O)CC(C(O)=CC(O)=C2[C@H]3C4=C(O)C=C(O)C=C4O[C@@H]([C@@H]3O)C=3C=CC(O)=CC=3)=C2O1 JPFCOVZKLAXXOE-XBNSMERZSA-N 0.000 description 2
206010003210 Arteriosclerosis Diseases 0.000 description 2
241000551547 Dione <red algae> Species 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 2
OEIJRRGCTVHYTH-UHFFFAOYSA-N Favan-3-ol Chemical compound OC1CC2=CC=CC=C2OC1C1=CC=CC=C1 OEIJRRGCTVHYTH-UHFFFAOYSA-N 0.000 description 2
108010046315 IDL Lipoproteins Proteins 0.000 description 2
235000019482 Palm oil Nutrition 0.000 description 2
229920001991 Proanthocyanidin Polymers 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
108010062497 VLDL Lipoproteins Proteins 0.000 description 2
229930003427 Vitamin E Natural products 0.000 description 2
230000001133 acceleration Effects 0.000 description 2
238000000540 analysis of variance Methods 0.000 description 2
208000011775 arteriosclerosis disease Diseases 0.000 description 2
210000001367 artery Anatomy 0.000 description 2
239000003613 bile acid Substances 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
150000001840 cholesterol esters Chemical class 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
230000003111 delayed effect Effects 0.000 description 2
238000001514 detection method Methods 0.000 description 2
230000037213 diet Effects 0.000 description 2
230000000378 dietary effect Effects 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
239000002270 dispersing agent Substances 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
229930003944 flavone Natural products 0.000 description 2
150000002213 flavones Chemical class 0.000 description 2
235000011949 flavones Nutrition 0.000 description 2
235000011389 fruit/vegetable juice Nutrition 0.000 description 2
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
239000008187 granular material Substances 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
208000020346 hyperlipoproteinemia Diseases 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
108010022197 lipoprotein cholesterol Proteins 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000005259 measurement Methods 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
239000004005 microsphere Substances 0.000 description 2
239000002540 palm oil Substances 0.000 description 2
150000007965 phenolic acids Chemical class 0.000 description 2
229920001993 poloxamer 188 Polymers 0.000 description 2
229940044519 poloxamer 188 Drugs 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
229940068968 polysorbate 80 Drugs 0.000 description 2
229920000053 polysorbate 80 Polymers 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000002265 prevention Effects 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
235000018102 proteins Nutrition 0.000 description 2
239000007921 spray Substances 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
239000012730 sustained-release form Substances 0.000 description 2
235000019165 vitamin E Nutrition 0.000 description 2
239000011709 vitamin E Substances 0.000 description 2
229940046009 vitamin E Drugs 0.000 description 2
238000004260 weight control Methods 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
DMBUODUULYCPAK-UHFFFAOYSA-N 1,3-bis(docosanoyloxy)propan-2-yl docosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCCCC DMBUODUULYCPAK-UHFFFAOYSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
101150102415 Apob gene Proteins 0.000 description 1
102000005666 Apolipoprotein A-I Human genes 0.000 description 1
108010059886 Apolipoprotein A-I Proteins 0.000 description 1
102000018619 Apolipoproteins A Human genes 0.000 description 1
108010027004 Apolipoproteins A Proteins 0.000 description 1
102000018616 Apolipoproteins B Human genes 0.000 description 1
108010027006 Apolipoproteins B Proteins 0.000 description 1
206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
108010004103 Chylomicrons Proteins 0.000 description 1
235000008733 Citrus aurantifolia Nutrition 0.000 description 1
235000005979 Citrus limon Nutrition 0.000 description 1
244000131522 Citrus pyriformis Species 0.000 description 1
229920002911 Colestipol Polymers 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
CITFYDYEWQIEPX-UHFFFAOYSA-N Flavanol Natural products O1C2=CC(OCC=C(C)C)=CC(O)=C2C(=O)C(O)C1C1=CC=C(O)C=C1 CITFYDYEWQIEPX-UHFFFAOYSA-N 0.000 description 1
HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
235000010469 Glycine max Nutrition 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
108010028554 LDL Cholesterol Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
235000001412 Mediterranean diet Nutrition 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
QSLJIVKCVHQPLV-PEMPUTJUSA-N Oxandrin Chemical compound C([C@@H]1CC2)C(=O)OC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 QSLJIVKCVHQPLV-PEMPUTJUSA-N 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
239000004141 Sodium laurylsulphate Substances 0.000 description 1
239000004147 Sorbitan trioleate Substances 0.000 description 1
PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
244000269722 Thea sinensis Species 0.000 description 1
208000024799 Thyroid disease Diseases 0.000 description 1
235000011941 Tilia x europaea Nutrition 0.000 description 1
240000006909 Tilia x europaea Species 0.000 description 1
240000001717 Vaccinium macrocarpon Species 0.000 description 1
235000012545 Vaccinium macrocarpon Nutrition 0.000 description 1
235000002118 Vaccinium oxycoccus Nutrition 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000003957 anion exchange resin Substances 0.000 description 1
239000003524 antilipemic agent Substances 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
230000004872 arterial blood pressure Effects 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
KBFXONBVEJPQLK-UHFFFAOYSA-N benzoylsulfamic acid Chemical class OS(=O)(=O)NC(=O)C1=CC=CC=C1 KBFXONBVEJPQLK-UHFFFAOYSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
235000019577 caloric intake Nutrition 0.000 description 1
239000000969 carrier Substances 0.000 description 1
ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
235000005487 catechin Nutrition 0.000 description 1
150000001765 catechin Chemical class 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
208000029755 cholesterol metabolism disease Diseases 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
235000019504 cigarettes Nutrition 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
229960002577 colestipol hydrochloride Drugs 0.000 description 1
239000003086 colorant Substances 0.000 description 1
229920002770 condensed tannin Polymers 0.000 description 1
208000026758 coronary atherosclerosis Diseases 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
239000006184 cosolvent Substances 0.000 description 1
235000004634 cranberry Nutrition 0.000 description 1
239000006071 cream Substances 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
229960001767 dextrothyroxine Drugs 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
UMNKXPULIDJLSU-UHFFFAOYSA-N dichlorofluoromethane Chemical compound FC(Cl)Cl UMNKXPULIDJLSU-UHFFFAOYSA-N 0.000 description 1
229940099364 dichlorofluoromethane Drugs 0.000 description 1
229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000002651 drug therapy Methods 0.000 description 1
238000007908 dry granulation Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
229930182497 flavan-3-ol Natural products 0.000 description 1
235000011987 flavanols Nutrition 0.000 description 1
229930003949 flavanone Natural products 0.000 description 1
150000002208 flavanones Chemical class 0.000 description 1
235000011981 flavanones Nutrition 0.000 description 1
HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
150000002216 flavonol derivatives Chemical class 0.000 description 1
235000011957 flavonols Nutrition 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000019264 food flavour enhancer Nutrition 0.000 description 1
235000015203 fruit juice Nutrition 0.000 description 1
229960003627 gemfibrozil Drugs 0.000 description 1
235000006539 genistein Nutrition 0.000 description 1
229940045109 genistein Drugs 0.000 description 1
TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
239000012943 hotmelt Substances 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
230000000260 hypercholesteremic effect Effects 0.000 description 1
239000007943 implant Substances 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
150000002515 isoflavone derivatives Chemical class 0.000 description 1
235000008696 isoflavones Nutrition 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229960001375 lactose Drugs 0.000 description 1
239000004571 lime Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000003550 marker Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
238000002483 medication Methods 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
GACQNVJDWUAPFY-UHFFFAOYSA-N n'-[2-[2-(2-aminoethylamino)ethylamino]ethyl]ethane-1,2-diamine;hydrochloride Chemical compound Cl.NCCNCCNCCNCCN GACQNVJDWUAPFY-UHFFFAOYSA-N 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
229960001652 norethindrone acetate Drugs 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000002674 ointment Substances 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
229960002969 oleic acid Drugs 0.000 description 1
229960000464 oxandrolone Drugs 0.000 description 1
PLQIOFZPHAZJAM-UHFFFAOYSA-N oxo(phenyl)methanesulfonamide Chemical class NS(=O)(=O)C(=O)C1=CC=CC=C1 PLQIOFZPHAZJAM-UHFFFAOYSA-N 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
235000009048 phenolic acids Nutrition 0.000 description 1
235000017807 phytochemicals Nutrition 0.000 description 1
239000000049 pigment Substances 0.000 description 1
229930000223 plant secondary metabolite Natural products 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229930182496 polymethoxyflavone Natural products 0.000 description 1
150000008442 polyphenolic compounds Chemical class 0.000 description 1
230000002028 premature Effects 0.000 description 1
239000000955 prescription drug Substances 0.000 description 1
238000009117 preventive therapy Methods 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
235000004252 protein component Nutrition 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
230000000391 smoking effect Effects 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
229940045902 sodium stearyl fumarate Drugs 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
235000019337 sorbitan trioleate Nutrition 0.000 description 1
229960000391 sorbitan trioleate Drugs 0.000 description 1
239000012798 spherical particle Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
229940032147 starch Drugs 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000013589 supplement Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
238000012353 t test Methods 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
229960000984 tocofersolan Drugs 0.000 description 1
229930003799 tocopherol Natural products 0.000 description 1
239000011732 tocopherol Substances 0.000 description 1
229960001295 tocopherol Drugs 0.000 description 1
235000010384 tocopherol Nutrition 0.000 description 1
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
229940029284 trichlorofluoromethane Drugs 0.000 description 1
DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
238000005550 wet granulation Methods 0.000 description 1
QUEDXNHFTDJVIY-DQCZWYHMSA-N γ-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-DQCZWYHMSA-N 0.000 description 1
GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Natural Medicines & Medicinal Plants (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medical Informatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Botany (AREA)
Alternative & Traditional Medicine (AREA)
Microbiology (AREA)
Mycology (AREA)
Biotechnology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Diabetes (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Plant Substances (AREA)
Medicinal Preparation (AREA)

ZA200610168A 2004-05-26 2005-05-24 Compositions comprising flavonoids and tocotrienols and methods thereof ZA200610168B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US57449004P	2004-05-26	2004-05-26

Publications (1)

Publication Number	Publication Date
ZA200610168B true ZA200610168B (en)	2008-06-25

Family

ID=35450644

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200610168A ZA200610168B (en)	2004-05-26	2005-05-24	Compositions comprising flavonoids and tocotrienols and methods thereof

Country Status (11)

Country	Link
US (2)	US20060013901A1 (fr)
EP (1)	EP1748774B1 (fr)
KR (1)	KR20070088325A (fr)
CN (1)	CN101001624A (fr)
AT (1)	ATE491447T1 (fr)
AU (1)	AU2005247162A1 (fr)
CA (1)	CA2567969A1 (fr)
DE (1)	DE602005025339D1 (fr)
IL (1)	IL179544A0 (fr)
WO (1)	WO2005115378A1 (fr)
ZA (1)	ZA200610168B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20070088326A (ko) *	2004-05-26	2007-08-29	케이지케이 시너자이즈 인코포레이티드	종양성 질환 및 염증을 치료하기 위한 약제학적 생성물
KR20070088324A (ko) *	2004-05-26	2007-08-29	케이지케이 시너자이즈 인코포레이티드	플라보노이드 및 토코트리에놀을 포함하는 기능성 식품 및그에따른 방법
US20080166418A1 (en) *	2007-01-04	2008-07-10	Sones Scott F	Krill oil compositions
JP2008247826A (ja) *	2007-03-30	2008-10-16	Hiroshima Univ	血糖値調整剤およびまたは血中コレステロール値調整剤
EP2170331B1 (fr) *	2007-06-29	2014-12-03	Laboratoires Dr Ng Payot	Combinaison synergique de proanthocyanidines, de gamma-tocotriénol et de niacine
WO2014057727A1 (fr) *	2012-10-12	2014-04-17	国立大学法人琉球大学	Procédé de fabrication d'une substance contenant de la nobilétine et de la tangérétine dérivées de fruits d'agrumes, et substance contenant de la nobilétine et de la tangérétine ainsi obtenue
CN112451518B (zh) *	2012-11-13	2025-02-21	因维克特斯生物技术有限公司	生育三烯酚的经粘膜递送
US9132117B2 (en)	2013-06-17	2015-09-15	Kgk Synergize, Inc	Compositions and methods for glycemic control of subjects with impaired fasting glucose

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4603142A (en) *	1984-06-01	1986-07-29	Wisconsin Alumni Research Foundation	Cholesterol lowering method of use
US5217992A (en) *	1989-10-04	1993-06-08	Bristol-Myers Squibb Company	Tocotrienols in the treatment of hypercholesterolemia, hyperlipidemia and thromboembolic disorders
CA2283333A1 (fr) *	1997-03-04	1998-09-11	Charles E. Elson	Procede d'inhibition de la croissance de tumeurs utilisant des combinaisons d'isoprenoides et de statines
US6251400B1 (en) *	1997-09-26	2001-06-26	Kgk Synergize Inc	Compositions and methods of treatment of neoplastic diseases and hypercholesterolemia with citrus limonoids and flavonoids and tocotrienols
US6239114B1 (en) *	1997-09-26	2001-05-29	Kgk Synergize	Compositions and methods for treatment of neoplastic diseases with combinations of limonoids, flavonoids and tocotrienols
US20010055627A1 (en) *	1997-09-26	2001-12-27	Najla Guthrie	Compositions And Methods For Regulating Lipoproteins And Hypercholesterolemia With Limonoids, Flavonoids And Tocotrienols
KR20000019716A (ko) *	1998-09-15	2000-04-15	박호군	바이오플라보노이드 화합물을 포함하는 혈당 강하용 조성물
US6987125B1 (en) *	1998-10-06	2006-01-17	The United States Of America As Represented By The Secretary Of Agriculture	Compositions and methods of treating, reducing and preventing cardiovascular diseases and disorders with polymethoxyflavones
US6641847B1 (en) *	1999-06-01	2003-11-04	Ocean Spray Cranberries, Inc.	Cranberry seed oil extract and compositions containing components thereof
US20020006953A1 (en) *	1999-11-05	2002-01-17	Carla R. McGill	Modification of cholesterol concentrations with citus phytochemicals
WO2001070029A1 (fr) *	2000-03-17	2001-09-27	Kgk Synergie	Composition et methodes de traitement, de diminution, et de prevention de maladies et troubles cardio-vasculaires avec des polymethoxyflavones
US20020054924A1 (en) *	2000-04-13	2002-05-09	Leahy Margaret M.	Novel compositions derived from cranberry and grapefruit and therapeutic uses therefor
US6579544B1 (en) *	2000-05-31	2003-06-17	Nutriex, L.L.C.	Method for supplementing the diet
AU2001290166A1 (en) *	2000-09-15	2002-03-26	Kgk Synergize	Components of canola for treating hyperlipidemia
US20020090405A1 (en) *	2000-09-15	2002-07-11	Najla Guthrie	Components of canola for the treatment of cancer
GB0026018D0 (en) *	2000-10-24	2000-12-13	Novartis Nutrition Ag	New composition
WO2002055071A1 (fr) *	2001-01-15	2002-07-18	Kgk Synergize	Compositions et methodes de regulation du taux de lipoproteines et de l'hypercholesterolemie au moyen de limonoides, de flavonoides et de tocotrienols
AU2002308324B2 (en) *	2001-05-02	2008-04-03	Kgk Synergize Inc.	Polymethoxylated flavones for treating insulin resistance
US7074825B2 (en) *	2002-03-07	2006-07-11	Huanbiao Mo	Composition and method for treating cancer
EP1415549A1 (fr) *	2002-11-01	2004-05-06	Galileo Laboratories, Inc.	Combination antioxydante synergistique de tocoles et de polyphénoles
US20050227930A1 (en) *	2004-04-08	2005-10-13	Kgk Synergize Inc.	Cholesterol lowering combination
KR20070088326A (ko) *	2004-05-26	2007-08-29	케이지케이 시너자이즈 인코포레이티드	종양성 질환 및 염증을 치료하기 위한 약제학적 생성물

2005
- 2005-05-24 ZA ZA200610168A patent/ZA200610168B/en unknown
- 2005-05-24 CN CNA2005800253593A patent/CN101001624A/zh active Pending
- 2005-05-24 DE DE602005025339T patent/DE602005025339D1/de not_active Expired - Lifetime
- 2005-05-24 US US11/135,693 patent/US20060013901A1/en not_active Abandoned
- 2005-05-24 CA CA002567969A patent/CA2567969A1/fr not_active Abandoned
- 2005-05-24 EP EP05743969A patent/EP1748774B1/fr not_active Expired - Lifetime
- 2005-05-24 AU AU2005247162A patent/AU2005247162A1/en not_active Abandoned
- 2005-05-24 WO PCT/IB2005/001427 patent/WO2005115378A1/fr not_active Ceased
- 2005-05-24 KR KR1020067027108A patent/KR20070088325A/ko not_active Ceased
- 2005-05-24 AT AT05743969T patent/ATE491447T1/de not_active IP Right Cessation
2006
- 2006-11-23 IL IL179544A patent/IL179544A0/en unknown
2008
- 2008-11-10 US US12/268,051 patent/US20090156665A1/en not_active Abandoned

Also Published As

Publication number	Publication date
ATE491447T1 (de)	2011-01-15
WO2005115378A1 (fr)	2005-12-08
EP1748774A1 (fr)	2007-02-07
WO2005115378B1 (fr)	2006-02-16
CA2567969A1 (fr)	2005-12-08
CN101001624A (zh)	2007-07-18
IL179544A0 (en)	2007-07-04
KR20070088325A (ko)	2007-08-29
EP1748774A4 (fr)	2007-12-19
US20060013901A1 (en)	2006-01-19
EP1748774B1 (fr)	2010-12-15
AU2005247162A1 (en)	2005-12-08
US20090156665A1 (en)	2009-06-18
DE602005025339D1 (de)	2011-01-27

Publication	Publication Date	Title
O’byrne et al.	2000	Studies of LDL oxidation following α-, γ-, or δ-tocotrienyl acetate supplementation of hypercholesterolemic humans
US20060003947A1 (en)	2006-01-05	Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols
Phelps et al.	1993	Garlic supplementation and lipoprotein oxidation susceptibility
US20090156665A1 (en)	2009-06-18	Compositions Comprising Flavonoids and Toctrienols and Methods Thereof
US20010055627A1 (en)	2001-12-27	Compositions And Methods For Regulating Lipoproteins And Hypercholesterolemia With Limonoids, Flavonoids And Tocotrienols
US20090156663A1 (en)	2009-06-18	Functional Foods Comprising Flavonoids and Tocotrienols and Methods Thereof
US7989006B2 (en)	2011-08-02	Annatto extract compositions, including geranyl geraniols and methods of use
US6987125B1 (en)	2006-01-17	Compositions and methods of treating, reducing and preventing cardiovascular diseases and disorders with polymethoxyflavones
CA2521149C (fr)	2014-03-25	Compositions d'extrait de rocou contenant des geranylgeraniols et modes d'utilisation
US20050227930A1 (en)	2005-10-13	Cholesterol lowering combination
US7012067B2 (en)	2006-03-14	Blood lipid ameliorant composition
Carpenter et al.	2003	Oral a-tocopherol supplementation inhibits lipid oxidation in established human atherosclerotic lesions
US20020090404A1 (en)	2002-07-11	Components of canola for treating hyperlipidemia
US20050249803A1 (en)	2005-11-10	Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols
US6358997B1 (en)	2002-03-19	Tocopherol and tocotrienol compositions
AU2013205995A1 (en)	2013-06-13	Compositions comprising flavonoids and tocotrienols and methods thereof
JP2008513350A (ja)	2008-05-01	フラボノイドとトコトリエノールを含む組成物及びその方法
JP2008513349A (ja)	2008-05-01	フラボノイドとトコトリエノールを含む機能性食品及びその方法
WO2021170806A1 (fr)	2021-09-02	Utilisations et compositions à base de polyphénols pour améliorer la biodisponibilité orale de l'hydroxytyrosol
WO1996019218A1 (fr)	1996-06-27	Compositions de tocopherols et de tocotrienols
US20060182828A1 (en)	2006-08-17	Methods of reducing lipid peroxidation and achieving related health benefits by the administration of tocopherol and sesame lignans
CN114177185B (zh)	2022-06-17	一种用于降低胆固醇与预防心血管疾病的药物组合物
Papas	2002	Vitamin E: a new perspective
AU2013205996A1 (en)	2013-06-13	Functional foods comprising flavonoids and tocotrienols and methods thereof
Ghulam Rasool	2005	Effect Of Commercially Available Vitamin E Preparations On Arterial Compliance And Selected Cardiovascular Parameters [QP772. T6 A288 2006 f rb].